HOME >> MEDICINE >> NEWS
Chemical engineers suggest Alzheimer's onset tied To cholesterol, brain chemicals

COLLEGE STATION, December 6 - Few people can look Alzheimer's disease in the face without flinching. Alzheimer's takes from people the things they value most: intellect, emotion, independence, hope -- and eventually, life itself.

Now, a group of unlikely Alzheimer's researchers -- chemical engineers in Texas A&M University's Dwight Look College of Engineering -- are developing new understanding of how the disease robs Alzheimer's sufferers of their memory and reason. They've also found hints of new ways to eventually prevent its onset.

Laboratory studies conducted by chemical engineer Theresa Good, an Assistant professor in the Department of Chemical Engineering, and Ph.D. students Dawn L. Rymer and Steven S. Wang, suggest that Alzheimer's onset and the damage it causes to memory and cognitive abilities are tied to two substances: cholesterol (the same cholesterol doctors say people have too much of) and a complex chemical called ganglioside GM-1 -- found in the brain cells it attacks.

Their work centers on an important characteristic of Alzheimer's disease, a build-up of masses of protein, known as senile plaques. These plaques attach, or bind, to neurons -- specialized cells that allow information to move from place to place in the brain. When the plaques attach to the neurons, it causes a biochemical process to begin that eventually kills the neurons. Loss of neurons is what brings on the disease's characteristic loss of memory and cognitive abilities. High levels of either cholesterol or ganglioside GM-1 seem to make it easy for the plaques to attach to neurons.

The good news is that Good's research also suggests that reducing the amount of either cholesterol or ganglioside GM-1 interferes with the plaque's ability to attach to the neurons. In fact, simply reducing the amount of cholesterol in the cells seems to block attachment by almost all of the
'"/>

Contact: Mark Evans
mark-evans@tamu.edu
979-458-3597
Texas A&M University
6-Dec-2001


Page: 1 2

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Chemicals in tattoo inks need closer scrutiny
3. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
4. Chemicals found in cherries may help fight diabetes
5. Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment
6. Health benefits of citrus topic at American Chemical Society meeting in Philadelphia
7. Chemical brain scans may help reassure brain tumor patients
8. US DoE awards $4 million in funding to Stevens Center for MicroChemical Systems
9. Chemical & Engineering News 80th anniversary issue highlights periodic table
10. Chemical turns stem cells into neurons say scientists at Scripps Research Institute
11. Brookhaven spotlights: News from the March 2003 American Chemical Society Meeting

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: